Steve Cohen's Point72 Asset Management fully liquidated its position in BioMarin Pharmaceutical Inc. (BMRN) during the second quarter of 2026. The firm sold its entire holding of 1.20 million shares, which was previously valued at approximately $67.74 million. This trade brings Point72's portfolio weight in the biotechnology company from 0.09% to zero, marking a complete exit from the investment.
It is important to remember that large investment firms are required to disclose their holdings quarterly in 13F filings, which are released with a delay. This particular disclosure, filed on August 14, 2026, reflects trading activity that occurred between April 1 and June 30, 2026, and does not necessarily represent the firm's current holdings.